T cells are immune cells that fight infection. In T-cell immunotherapy, some T cells are removed from a patient’s blood. Then, the cells are changed in a laboratory, so they have specific proteins called receptors. The receptors allow those T cells to recognize the cancer cells. The changed T cells are grown in the laboratory and returned to the patient’s body. Once there, they seek out and destroy cancer cells.
|CAR-T (Chimeric Antigen Receptor)|
|TCR-T (T-Cell Receptor)|
HPV-associated cancers, such as:
|TAA-T (Tumor-Associated Antigen)|
Variety of advanced cancers, such as pancreatic cancer, bladder cancer, ovarian cancer, etc.
|TIL (Tumor Infiltrating Lymphocytes)|
Variety of advanced cancers, such as glioma, colon cancer, breat cancer, colorectal cancer with liver metastases, etc.
|scFv ICI (Short chain fragment Immune checkpoint inhibitors – cells or soluble ICI)|
Variety of advanced cancers, such as Non-Small Cell lung Cancer (NSCLC), advanced metastatic breast cancer, etc.
This decade, a lot of clinical trials regarding CAR-T therapy were carried out around the word. As of April 19, 2018, the information from Clinicaltrails.gov showed that more than 270 CAR-T related studies were undergoing clinical trials in many different countries.
By analyzing the overall response rate (ORR) and complete response rate (CRR) of CAR-T therapy in patients with different tumors, we found that the response rate was significantly higher for patients with hematologic malignancies compared to patients with solid malignancies.